Physician
Johnson Memorial Hospital, INC.
Johnson Memorial Hospital, INC. was paid $22.35M by Medicaid between Jan 2018 and Dec 2024, across 220 billing codes. Its largest line is 99285, emergency room visit (most serious) — 27% of everything it billed.
33Billing provider infoJOHNSON MEMORIAL HOSPITAL, INC.
STAFFORD SPRINGS, CT 06076
STAFFORD SPRINGS, CT 06076
33aNPI1972728442assigned 04/17/2007
33bProvider typeCardiovascular Disease Physician
28Total paid$22.35M
24GClaims701,586
24DCodes billed220
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiovascular Disease Physician providers in Connecticut
Rank by total paid#2 of 48
Median peer was paid$37K
This provider vs. median599×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 87,513 | $2.87M | |
| 2019 | 92,838 | $3.11M | |
| 2020 | 77,890 | $2.64M | |
| 2021 | 110,334 | $3.69M | |
| 2022 | 111,369 | $3.58M | |
| 2023 | 116,424 | $3.42M | |
| 2024incomplete | 105,218 | $3.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 27% | 14,901 | 12,751 | $6.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 12,628 | 10,998 | $3.55M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 14,948 | 13,279 | $2.99M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.9% | 11,141 | 9,197 | $1.53M |
| 97010 | 4.1% | 14,829 | 4,370 | $915K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 4,623 | 4,085 | $829K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 8,854 | 3,095 | $500K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.1% | 852 | 695 | $468K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 4,126 | 3,577 | $408K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 8,593 | 6,780 | $386K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 2,859 | 2,396 | $369K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 7,921 | 6,159 | $348K |
208 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 2,726 | $322K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 2,544 | $306K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 5,683 | $290K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 3,415 | $256K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,534 | $219K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,511 | $206K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,518 | $183K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 795 | $161K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 201 | $153K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,225 | $151K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 583 | $128K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 308 | $122K |
| 97597 | <1% | 1,250 | $114K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 772 | $104K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,507 | $86K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 126 | $83K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 437 | $74K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,765 | $68K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 286 | $56K |
| 82947 | <1% | 18,712 | $48K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 533 | $48K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 441 | $46K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 35,739 | $43K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,061 | $39K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,385 | $33K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 248 | $28K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 320 | $27K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,527 | $26K |
| 93971 | <1% | 446 | $26K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,109 | $25K |
| 0002A | <1% | 672 | $24K | |
| 0001A | <1% | 767 | $22K | |
| 83718 | <1% | 2,914 | $20K | |
| 72100 | <1% | 806 | $20K | |
| 97162 | <1% | 408 | $20K | |
| 86900 | <1% | 1,325 | $19K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,347 | $19K |
| 76801 | <1% | 170 | $18K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 291 | $18K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,601 | $17K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 38 | $17K |
| 94060 | <1% | 98 | $16K | |
| 82247 | <1% | 14,757 | $15K | |
| 82040 | <1% | 7,117 | $15K | |
| 76830 | Ultrasound, transvaginal | <1% | 161 | $15K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,158 | $15K |
| 97014 | <1% | 205 | $14K | |
| 82607 | <1% | 1,981 | $14K | |
| 97035 | <1% | 263 | $13K | |
| 82728 | <1% | 2,059 | $12K | |
| 82310 | <1% | 18,649 | $11K | |
| 80053 | Comprehensive metabolic panel | <1% | 5,443 | $10K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 120 | $9K |
| 83550 | <1% | 2,232 | $9K | |
| 93017 | <1% | 158 | $9K | |
| 73562 | <1% | 953 | $8K | |
| 71250 | <1% | 140 | $8K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 243 | $8K |
| 80061 | Lipid panel | <1% | 2,321 | $7K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 73 | $7K |
| 73030 | <1% | 836 | $7K | |
| 83540 | <1% | 2,311 | $7K | |
| 73630 | <1% | 948 | $6K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 126 | $6K |
| 84439 | <1% | 1,188 | $6K | |
| 73610 | <1% | 939 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,460 | $5K |
| 36591 | <1% | 174 | $5K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,980 | $4K |
| 74018 | <1% | 158 | $4K | |
| 86618 | <1% | 738 | $3K | |
| 73130 | <1% | 522 | $3K | |
| 82746 | <1% | 423 | $3K | |
| 83735 | <1% | 6,684 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 180 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,925 | $3K |
| 85610 | <1% | 4,779 | $3K | |
| 82374 | <1% | 18,657 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 21 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,224 | $2K |
| 82465 | <1% | 2,929 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,323 | $2K |
| 82570 | <1% | 601 | $2K | |
| 86140 | <1% | 868 | $2K | |
| 85652 | <1% | 1,527 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 14 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 84 | $1K |
| 0012A | <1% | 93 | $1K | |
| 96367 | <1% | 23 | $1K | |
| 93970 | <1% | 15 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 120 | $1K |
| 82043 | <1% | 412 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 72 | $1K |
| 83880 | <1% | 2,013 | $1K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 243 | $852.22 |
| 73110 | <1% | 165 | $826.38 | |
| 85730 | <1% | 1,029 | $786.72 | |
| 81001 | <1% | 6,146 | $777.01 | |
| 83690 | <1% | 9,733 | $718.06 | |
| 82565 | <1% | 19,021 | $704.29 | |
| 0011A | <1% | 93 | $700.38 | |
| 12001 | <1% | 40 | $586.20 | |
| 83615 | <1% | 8,989 | $483.51 | |
| 82150 | <1% | 7,193 | $445.63 | |
| 73502 | <1% | 79 | $407.76 | |
| 84153 | <1% | 43 | $407.60 | |
| 87186 | <1% | 1,367 | $391.47 | |
| 85379 | <1% | 2,351 | $379.44 | |
| 85027 | <1% | 335 | $366.48 | |
| 72040 | <1% | 15 | $331.73 | |
| 81003 | <1% | 4,625 | $292.73 | |
| 84484 | <1% | 7,346 | $275.75 | |
| 84478 | <1% | 2,938 | $223.06 | |
| 80076 | <1% | 344 | $210.18 | |
| 87581 | <1% | 21 | $201.06 | |
| 87486 | <1% | 21 | $201.06 | |
| 82248 | <1% | 9,001 | $196.21 | |
| 73080 | <1% | 14 | $194.97 | |
| 87040 | <1% | 2,084 | $189.75 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,562 | $182.42 |
| 84702 | <1% | 101 | $144.82 | |
| 84450 | <1% | 14,851 | $131.42 | |
| 86703 | <1% | 14 | $130.90 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 78 | $123.29 |
| 84550 | <1% | 181 | $122.87 | |
| 87070 | <1% | 1,264 | $119.68 | |
| 83605 | <1% | 3,574 | $116.21 | |
| 96376 | <1% | 2,312 | $115.60 | |
| 82550 | <1% | 895 | $109.32 | |
| 84703 | <1% | 624 | $106.83 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 616 | $100.44 |
| 86753 | <1% | 96 | $94.64 | |
| 82784 | <1% | 14 | $86.28 | |
| 84520 | <1% | 18,890 | $85.25 | |
| 84460 | <1% | 14,866 | $69.89 | |
| 82435 | <1% | 18,656 | $67.55 | |
| 81025 | <1% | 1,303 | $67.08 | |
| 71100 | <1% | 29 | $66.04 | |
| 82077 | <1% | 2,374 | $61.80 | |
| 84075 | <1% | 14,778 | $48.87 | |
| 87430 | <1% | 898 | $46.39 | |
| 84132 | <1% | 18,735 | $44.56 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,770 | $41.20 |
| 82962 | <1% | 4,376 | $29.84 | |
| 87077 | <1% | 303 | $26.40 | |
| 87147 | <1% | 93 | $26.15 | |
| 84100 | <1% | 251 | $20.85 | |
| 86666 | <1% | 35 | $19.44 | |
| 87088 | <1% | 136 | $16.67 | |
| 84155 | <1% | 6,945 | $15.24 | |
| 84295 | <1% | 18,689 | $13.87 | |
| 82553 | <1% | 528 | $11.02 | |
| 81015 | <1% | 100 | $2.69 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 95 | $2.57 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,808 | $1.80 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 84 | $0.39 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 61 | $0.16 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 55 | $0.15 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 7,121 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,634 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 6,624 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 35 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,224 | $0.00 |
| 94727 | 0% | 98 | $0.00 | |
| 87400 | 0% | 856 | $0.00 | |
| 90715 | 0% | 341 | $0.00 | |
| 88313 | 0% | 189 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 353 | $0.00 |
| 91300 | 0% | 1,383 | $0.00 | |
| 93041 | 0% | 809 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 352 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 214 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 135 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 218 | $0.00 |
| 94729 | 0% | 98 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 45 | $0.00 |
| 84145 | 0% | 20 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 78 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 13 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 14 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 12 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 1,091 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 2,474 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 4,664 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,239 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 2,455 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 730 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 61 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 7,402 | $0.00 |
| 86901 | 0% | 1,325 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 60 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 1,243 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 512 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 65 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,140 | $0.00 |
| 86850 | 0% | 1,298 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,414 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 362 | $0.00 |
| J3490 | Unclassified drugs | 0% | 32,558 | $0.00 |
| 88342 | 0% | 99 | $0.00 | |
| 91301 | 0% | 123 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 111 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 29 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 18 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 42 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 84 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 14 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROOSE, ROBERT (PRESIDENT)
Parent organizationTRINITY HEALTH - NEW ENGLAND, INC.
| Provider | Location | Paid |
|---|---|---|
| Johnson Memorial Hospital, INC. | Stafford Springs, CT | $19K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.